Committee Name: Health Technology Expert Review Panel (HTERP)
Dr. Jean-Éric Tarride — Conflict of Interest Disclosure (Dated December 2018)
Dr. Tarride has previously been engaged by Janssen and Allergan to lead educational workshops on health technology assessment. He has received research funding or grants from AstraZeneca, Amgen, CSL Behring, Novo Nordisk, Sage, Assurex/Myriad, and Edwards Lifesciences for various health technology assessments, economic evaluations, and burden-of-illness studies.

Dr. Tarride has also been compensated by AstraZeneca, Pfizer Inc., GSK (GlaxoSmithKline), Edwards Lifesciences, Roche, Evidera, the European Commission Initiative on Breast Cancer (ECIBC), Amgen, PCDI Canada, and Novartis for providing advice around overall methodology and health technology assessment methods, and issues pertaining to market access including study design, cost-effectiveness, and reimbursement issues for various products across therapeutic areas.